ATE506350T1 - Alkylsulfoxidchinoline als nk-3-rezeptorliganden - Google Patents

Alkylsulfoxidchinoline als nk-3-rezeptorliganden

Info

Publication number
ATE506350T1
ATE506350T1 AT06784189T AT06784189T ATE506350T1 AT E506350 T1 ATE506350 T1 AT E506350T1 AT 06784189 T AT06784189 T AT 06784189T AT 06784189 T AT06784189 T AT 06784189T AT E506350 T1 ATE506350 T1 AT E506350T1
Authority
AT
Austria
Prior art keywords
alkylsulfoxidequinolines
receptor ligands
ligands
receptor
Prior art date
Application number
AT06784189T
Other languages
English (en)
Inventor
Jeffrey Albert
Gerard Koether
Cristobal Alhambra
James Kang
Thomas Simpson
James Woods
Yan Li
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37889114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE506350(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE506350T1 publication Critical patent/ATE506350T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT06784189T 2005-09-21 2006-09-19 Alkylsulfoxidchinoline als nk-3-rezeptorliganden ATE506350T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71927505P 2005-09-21 2005-09-21
US71928605P 2005-09-21 2005-09-21
PCT/SE2006/001068 WO2007035158A1 (en) 2005-09-21 2006-09-19 Alkyl sulfoxide quinolines as nk-3 receptor ligands

Publications (1)

Publication Number Publication Date
ATE506350T1 true ATE506350T1 (de) 2011-05-15

Family

ID=37889114

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06784189T ATE506350T1 (de) 2005-09-21 2006-09-19 Alkylsulfoxidchinoline als nk-3-rezeptorliganden

Country Status (17)

Country Link
US (1) US7964733B2 (de)
EP (1) EP1928835B1 (de)
JP (1) JP2009508946A (de)
KR (1) KR20080046669A (de)
AR (1) AR057130A1 (de)
AT (1) ATE506350T1 (de)
AU (1) AU2006292849A1 (de)
BR (1) BRPI0616136A2 (de)
CA (1) CA2621062A1 (de)
DE (1) DE602006021440D1 (de)
EC (1) ECSP088375A (de)
IL (1) IL189857A0 (de)
NO (1) NO20081862L (de)
RU (1) RU2008110914A (de)
TW (1) TW200800902A (de)
UY (1) UY29805A1 (de)
WO (1) WO2007035158A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1940795A1 (de) * 2005-09-21 2008-07-09 AstraZeneca AB N-oxo-heterocyclyl- und n-oxo-alkylchinolin-4-carbonsäureamide als liganden des nk-3-rezeptors
CA2681466A1 (en) * 2007-03-19 2008-09-25 Astrazeneca Ab Quinoline derivatives, pharmaceutical compositions comprising them, and their use in treating central nervous system and peripheral diseases
EP2139882B1 (de) * 2007-03-23 2013-12-25 Amgen Inc. 3- substituierte chinolin- oder chinoxalin- derivate und ihre verwendung als phosphatidylinositol 3-kinase (pi3k) inhibitoren

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK282721B6 (sk) 1994-05-27 2002-11-06 Smithkline Beecham S.P.A. Nepeptidové NK3 antagonistické látky, spôsob ich výroby, farmaceutické prostriedky s ich obsahom a ich použitie
IT1270615B (it) 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina
GB9502644D0 (en) 1995-02-10 1995-03-29 Zeneca Ltd Heterocyclic derivatives
GB9513118D0 (en) 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
GB9524137D0 (en) * 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
BR9611820A (pt) 1995-11-24 1999-07-13 Smithkline Beecham Spa Derivados de quinolina
AR004735A1 (es) 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
EP0983262B1 (de) 1997-05-23 2003-07-09 GlaxoSmithKline S.p.A. Chinolin-4-carboxamidderivate als nk-2 und nk-3 rezeptor antagonisten
AP1201A (en) * 1997-09-17 2003-09-01 Smithkline Beecham Corp Method for the synthesis of quinoline derivatives.
JP2002530377A (ja) 1998-11-20 2002-09-17 スミスクライン・ビーチャム・ソシエタ・ペル・アチオニ Nk−3およびnk−2受容体アンタゴニストとしてのキノリン−4−カルボキシアミド誘導体
WO2000064877A1 (en) 1999-04-26 2000-11-02 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
GB0027701D0 (en) 2000-11-13 2000-12-27 Smithkline Beecham Spa Novel compounds
AU2002226356A1 (en) 2000-11-28 2002-06-11 Glaxosmithkline S.P.A. Quinoline derivatives as nk-3 antagonists
WO2002043734A1 (en) 2000-11-28 2002-06-06 Glaxosmithkline Spa Novel compounds
DE60209362T2 (de) 2001-04-11 2006-10-26 Glaxosmithkline S.P.A. 3-substituierte chinolin-4-carbonsäureamidderivate als nk-3- und nk-2-rezeptorantagonisten
GB0109122D0 (en) 2001-04-11 2001-05-30 Smithkline Beecham Spa Novel compounds
GB0318727D0 (en) 2003-08-08 2003-09-10 Smithkline Beecham Corp Novel compounds
GB0425075D0 (en) 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0425076D0 (en) 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0425077D0 (en) 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
JP2008546767A (ja) 2005-06-23 2008-12-25 アストラゼネカ・アクチエボラーグ Nk3受容体のモジュレーターとしてのキノリン3−スルホン酸エステル
AR058051A1 (es) * 2005-09-21 2008-01-23 Astrazeneca Ab Quinolinas de alquilnitrilo.proceso de obtencion y composiciones farmaceuticas.
EP1940795A1 (de) * 2005-09-21 2008-07-09 AstraZeneca AB N-oxo-heterocyclyl- und n-oxo-alkylchinolin-4-carbonsäureamide als liganden des nk-3-rezeptors
WO2007039123A2 (en) 2005-09-22 2007-04-12 Smithkline Beecham Corporation Combination therapy comprising an nk-3 antagonist and an antipsychotic agent
WO2007044251A2 (en) 2005-09-30 2007-04-19 Smithkline Beecham Corporation Pharmaceutical compositions

Also Published As

Publication number Publication date
AU2006292849A1 (en) 2007-03-29
JP2009508946A (ja) 2009-03-05
UY29805A1 (es) 2007-04-30
IL189857A0 (en) 2008-08-07
NO20081862L (no) 2008-06-16
AR057130A1 (es) 2007-11-14
EP1928835B1 (de) 2011-04-20
TW200800902A (en) 2008-01-01
CA2621062A1 (en) 2007-03-29
BRPI0616136A2 (pt) 2011-06-07
WO2007035158A1 (en) 2007-03-29
DE602006021440D1 (de) 2011-06-01
US20080214605A1 (en) 2008-09-04
EP1928835A1 (de) 2008-06-11
ECSP088375A (es) 2008-05-30
KR20080046669A (ko) 2008-05-27
US7964733B2 (en) 2011-06-21
RU2008110914A (ru) 2009-10-27

Similar Documents

Publication Publication Date Title
HUS2100054I1 (hu) Melanokortin receptor ligandumok
DE602006015607D1 (de) Thiazol-4-carboxamid-derivate als mglur5-antagonisten
EP2079466A4 (de) Substituierte indolverbindungen
FI20055649L (fi) Paikanmääritystekniikoita
DK1885966T3 (da) Forbedret hoved-t-forbindelse
DK1870409T3 (da) Benzimidazolforbindelser
DE602006015186D1 (de) Oxindole als kinaseinhibitoren
ATE506350T1 (de) Alkylsulfoxidchinoline als nk-3-rezeptorliganden
DE602006018334D1 (de) Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten
PL1999281T3 (pl) Ulepszona pionowa
DE602006021208D1 (de) Telefoneinrichtung
EP1915490A4 (de) Duchführungsanordnung
UA11896S (uk) Плічок для одягу
ITMI20050295U1 (it) Tovagliette sottopiatto migliorate
FR2882660B1 (fr) Evapo-reacteur vertical
FIU20050309U0 (fi) Pystyhirsirakenne
FIU20050215U0 (fi) Pyykkipoika
SE0502247L (sv) Referenslinje
UA10108S (uk) Вішалка-стояк для одягу
FI20055601A7 (fi) Kannatin
UA11842S (uk) Кронштейн
SE0601852L (sv) Hemolyseringsmedel
ES1061306Y (es) Mosquitera mejorada
UA12785S (uk) Тканина
UA12787S (uk) Тканина

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties